Julie Bowman Lowe, MD
Dermatology · Oklahoma City, OKNPI 1831121672
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,895 of the $4,986 with a category attached, or 78.1%. 19 manufacturers reported payments, led by Sanofi at 28.9% of the total.
Across 208 payments — averaging $23.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- Pfizer$1K
- UCB, Inc.$789
- Regeneron Healthcare Solutions, Inc.$247
- Johnson & Johnson$245
- Novartis$171
- plus $859 from 13 others
Across 128 payments — averaging $1738.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$116K
- AbbVie$106K
What the payments were for
- Travel & lodging$91818%
- Food & beverage$3,89578%
- Education$1723%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 71 | $1,442 |
| Pfizer | 7 | $1,233 |
| UCB, Inc. | 47 | $789 |
| Regeneron Healthcare Solutions, Inc. | 12 | $247 |
| Johnson & Johnson | 8 | $245 |
| Novartis | 12 | $171 |
| Galderma Laboratories, L.p. | 11 | $169 |
| VYNE Pharmaceuticals Inc. | 13 | $152 |
| AbbVie(2 entities) | 7 | $135 |
| LEO Pharma Inc. | 6 | $101 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Lilly USA, LLC | 4 | $67 |
| Sun Pharmaceutical Industries Inc. | 2 | $38 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $34 |
| Amgen | 1 | $24 |
| Arcutis Biotherapeutics, Inc. | 1 | $22 |
| Incyte Corporation | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Mayne Pharma Commercial LLC | 1 | $7 |
How this compares
$4,986 in reported general payments places this provider in the 55th percentile of 114 dermatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 13 | $95,554 |
| Dupixent PenDupilumab | 20 | $76,362 |
| ValacyclovirValacyclovir Hcl | 95 | $3,761 |
| Fluorouracil | 45 | $3,176 |
| Clobetasol Propionate | 76 | $3,048 |
| Doxycycline Monohydrate | 44 | $1,578 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 25 | $1,314 |
| Triamcinolone Acetonide | 67 | $1,063 |
| Ketoconazole | 43 | $990 |
| Doxycycline Hyclate | 26 | $876 |
| Clobetasol EmollientClobetasol Propionate/Emoll | 17 | $867 |
| Ciclopirox | 11 | $761 |
| Minoxidil | 103 | $755 |
| Clindamycin Phosphate | 25 | $755 |
| Desonide | 17 | $685 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Oklahoma City
- Yaohan LamOklahoma City$88K
- Kimberly JerdanOklahoma City$59K
- Mark DawkinsOklahoma City$56K
- Quy PhamOklahoma City$14K
- Sunita CrittendenOklahoma City$13K
- Tiffany BrazealOklahoma City$13K
- Robert LehrOklahoma City$11K
- Courtney CookOklahoma City$10K
- Clifford HendersonOklahoma City$9K
- Roy RindlerOklahoma City$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.